Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1367
Peer-review started: July 30, 2017
First decision: October 9, 2017
Revised: November 16, 2017
Accepted: December 6, 2017
Article in press: December 7, 2017
Published online: December 28, 2017
Processing time: 117 Days and 20.3 Hours
Liver injury in the setting of human immunodeficiency virus (HIV) infection is more commonly attributed to viral hepatitis or highly active antiretroviral treatment (HAART) toxicity. The severity of liver injury is an important cause of morbidity and mortality. The emergence of autoimmune diseases, particularly autoimmune hepatitis (AIH) in the setting of HIV infection, is rare. Previous reports indicate that elevated liver enzymes are a common denominator amongst these patients. We present two patients with HIV infection, on HAART, with virological suppression. Both patients presented with elevated liver enzymes, and following liver biopsies, were diagnosed with AIH. The clinical course of these patients underscore the therapeutic value of corticosteroids, and in some cases, addition of immunosuppression for AIH treatment.
Core tip: Liver damage is rarely caused by autoimmune disease in the setting of human immunodeficiency virus (HIV) infection. We describe a case series of two patients with a history of HIV, who presented with characteristic elevation in liver enzymes. Both patients were hepatitis C negative. Liver biopsies followed by histopathology confirmed the diagnosis of autoimmune hepatitis. Case 1 was treated by corticosteroids and azathioprine, while case 2 was treated by corticosteroids only. Both patients reported significant clinical improvement. These cases suggest that liver biopsy should be performed in HIV patients with unknown liver disease. Additionally, they underscore the need for further clinical studies to explore the role of corticosteroids and immunosuppression in the management of autoimmune hepatitis in HIV patients.